Thierry Laugel is a venture capital investor at Kurma Partners with 25+ years of experience who combines deep scientific training (PharmD, PhD in pharmacology) with hands-on biotech R&D experience before moving into venture capital, giving him an unusual end-to-end perspective from lab to market. He deliberately grows his own companies through Kurma, with roughly 40-50% of portfolios in vehicles that Kurma has proactively created from academic science or pharma spin-outs, often incubating them very frugally for years before inviting in co-investors once the inflection point is clear.
About their Fund
Kurma Partners operates two specialized healthcare franchises under one roof—Kurma Biofund for therapeutics and biotech company creation from academic labs, and Kurma Diagnostics for diagnostics and digital health—while offering a full innovation-to-growth continuum through its dedicated Growth Opportunities Fund that continues financing promising portfolio companies into scale-up rounds. The firm has built a systematic company-creation engine with major European research institutes like Institut Pasteur and VIB, spinning out academic research into venture-backed companies and providing portfolio companies with operational support through strategic partnerships like its alliance with Samsung Biologics for development and manufacturing capabilities.
















.jpeg)







.jpeg)











































































.png)
























































































































.jpeg)









.jpeg)




















































































